Comparative biochemical kinase activity analysis identifies rivoceranib as the most selective VEGFR-2 inhibitor compared with other TKIs with known activity against VEGFR-2
Seong Jang,Bill Strickland,Lynda Finis,Jeffrey J. Koojiman,Janneke J. Melis,Guido J. Zaman,Jan V. Tornout
